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Background. The global burden of childhood tuberculosis (TB) is estimated to be 0.5 million new cases per
year. Human immunodeﬁciency virus (HIV)–infected children are at high risk for TB. Diagnosis of TB in HIV-
infected children remains a major challenge.
Methods. We describe TB diagnosis and screening practices of pediatric antiretroviral treatment (ART)
programs in Africa, Asia, the Caribbean, and Central and South America. We used web-based questionnaires to
collect data on ART programs and patients seen from March to July 2012. Forty-three ART programs treating
children in 23 countries participated in the study.
Results. Sputummicroscopy and chest Radiograph were available at all programs, mycobacterial culture in 40
(93%) sites, gastric aspiration in 27 (63%), induced sputum in 23 (54%), and XpertMTB/RIF in 16 (37%) sites.
Screening practices to exclude active TB before starting ART included contact history in 41 sites (84%),
symptom screening in 38 (88%), and chest Radiograph in 34 sites (79%). The use of diagnostic tools was
examined among 146 children diagnosed with TB during the study period. Chest Radiograph was used in 125
(86%) children, sputum microscopy in 76 (52%), induced sputum microscopy in 38 (26%), gastric aspirate
microscopy in 35 (24%), culture in 25 (17%), and Xpert MTB/RIF in 11 (8%) children.
Conclusions. Induced sputum and Xpert MTB/RIF were infrequently available to diagnose childhood TB, and
screening was largely based on symptom identiﬁcation. There is an urgent need to improve the capacity of ART
programs in low- and middle-income countries to exclude and diagnose TB in HIV-infected children.
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INTRODUCTION
The global burden of tuberculosis (TB) was estimated to be
8.7 million new cases in 2011, and approximately 0.5 mil-
lionwere children [1].Children are at high risk of progression
to active TB and severe forms of TB. Young childrenwith im-
mature immune systems and human immunodeﬁciency virus
(HIV)–infected children with severe immune deﬁciency have
the highest risk of developing TB [2, 3]. Early mortality is a
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major issue among children starting antiretroviral treatment
(ART) with advanced immunodeﬁciency in sub-Saharan
Africa [4]. TB mortality and incidence in HIV-infected chil-
dren can be substantially reduced by provision of isoniazid
preventive therapy (IPT) following TB exposure and by
ART [5–7].However, TB-HIV co-infection poses signiﬁcant
therapeutic challenges due to overlapping drug toxicities,
medication load, and drug interactions [8, 9].
The diagnosis of childhood TB is complicated by the
paucibacillary nature of the disease in children, which may
be even more pronounced in HIV-coinfected patients [10].
Traditionally, the diagnosis of pediatric TB relies on expo-
sure history, chest radiography, tuberculin skin testing
(TST), and sputum smear microscopy [11, 12]. Molecular
tests have recently been introduced to improve TB diagno-
sis and detect drug resistance [13–15]. However, it is un-
known to what extent these approaches have been
implemented in pediatric ART programs, especially in
low- and middle-income countries.
We conducted a comprehensive survey among pediatric
ART programs from the International Epidemiologic
Databases to Evaluate AIDS (IeDEA) network, a large col-
laboration of ART programs in low- and middle-income
countries, with the aim of assessing the availability
and use of TB diagnostic tools, screening practices, and
treatment.
METHODS
Study Setting
The IeDEA collaboration (www.iedea.org) includes ART
programs from sub-Saharan Africa, the Caribbean,
Central and South America, Asia-Paciﬁc, and North
America [16]. For the present study, we surveyed ART pro-
grams treating children in low- and middle-income coun-
tries from the African IeDEA regions, the Caribbean,
Central and South American region, and Asia-Paciﬁc be-
tween March 1 and July 1, 2012. Participating sites as
well as members of the TB and pediatric IeDEA working
groups are listed in the Acknowledgments.
Data Collection and Deﬁnitions
Data on ART programs and patients seen during the study
period were collected using REDCap (http://project-
redcap.org/), a web-based platform to create online
questionnaires [17].The overall survey project and the par-
ticipating sites are described in detail elsewhere [18]. The
ﬁrst part of the survey collected data on program-level
characteristics related to the management of childhood
TB (availability of diagnostic tools, screening, and treat-
ment practices). The second part of the survey collected
individual data on active pediatric TB cases seen consecu-
tively during the study period (March 1–July 1, 2012) and
whose clinical data were available. Eighteen sites did not
contribute individual-level patient data because the data
collection was not covered by the local Institutional
Review Board (IRB) approval, because of logistical rea-
sons, or because no pediatric HIV-infected TB cases were
seen during the study period. TB cases were deﬁned
based on the local case deﬁnition; all received anti-TB
treatment.
Children were deﬁned as aged below 15 years at start of
ART. Sputum smear microscopy, mycobacterial culture,
Xpert MTB/RIF, chest radiograph, and TST were consid-
ered to be available for the diagnosis of childhood TB if
these tools were available on site or within 50 km of a
given ART program. Induced sputum or gastric aspiration
for the collection of TB samples were deﬁned as available
whenever these tools were reported to be part of the TB
screening practices of an ART program.
Statistical Analyses
Descriptive statistics were used to describe the characteris-
tics of participating ART programs, the characteristics of
pediatric TB patients seen during the study period, the
availability of diagnostic tools for pediatric TB, and the
screening and treatment practices. We used χ2 tests to as-
sess differences in the availability of pediatric TB diagnostic
tools by site characteristics.
If not otherwise stated, missing data were individually re-
covered from the sites. All analyses were performed in Stata
version 12.1 (Stata Corporation, College Station, TX).
Ethics Statement
Data were collected through IeDEA cohorts. Ethics com-
mittees and/or IRBs in all host countries approved the col-
lection and transfer of anonymized data. Where requested
per local regulations, informed consent was provided. In
addition, the Vanderbilt University Health Science
Committee (Nashville, TN), the Ethics Committee of the
University of Bern (Switzerland), and the University of
Cape Town (South Africa) approved the analyses of these
observational data for this speciﬁc project.
RESULTS
Characteristics of Participating Pediatric ART Programs
Seventy-one sites treating adults or children were invited
and 58 (81.7%) participated in the survey. Fifteen sites
were treating adults only. Here, we analyzed the data
from the 43 ART programs treating children across 23
countries. Of these, 11 (25.6%) sites were only treating
children and 32 (74.4%) were treating both adults and
children. Thirteen (30.2%) sites were primary health care
centers or clinics, 6 (14.0%) were secondary, district, or
provincial hospitals, and 23 (55.8%) were tertiary teaching
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or referral hospitals. Thirty-four sites (79.1%) were urban,
7 (16.3%) periurban, and 2 (4.6%) were rural (Table 1).
The geographical distribution of the 43 participating pe-
diatric ART programs is shown in Figure 1.
Availability of TB Diagnostics and Associated Factors
Sputum microscopy and chest radiograph were available
for the diagnosis of TB in all sites (43, 100%), mycobacte-
rial culture in 40 (93.0%), gastric aspiration in 27 (62.8%),
TST in 26 (60.5%), induced sputum in 23 (53.5%), and
Xpert MTB/RIF in 16 (37.2%) sites (Table 1). Eleven
(25.6%) sites had no access to either gastric aspiration or
induced sputum for specimen collection. When restricting
to childhood TB diagnostic tools available on site only (and
not distantly), we found that 34 programs (79.1%) had di-
rect access to radiographs, 31 (72.1%) to sputum micros-
copy, 19 (44.2%) to TST, 9 (20.9%) to mycobacterial
culture, and 9 programs (20.9%) had direct access to
Xpert MTB/RIF.
The availability of sputum collection and diagnostic
tools for pediatric TB by the characteristics of participating
ART programs is described in Table 2. The availability of
gastric aspiration was lower in East Africa and Southern
Africa than in the other regions (P < .001). In contrast,
the availability of induced sputum and Xpert MTB/RIF
did not signiﬁcantly vary across geographical regions.
Gastric aspiration (P = .04) and TST (P = .008) were avail-
able more often in urban sites than in periurban or rural
settings. Xpert MTB/RIF tended to be more frequently
available in larger ART programs that in smaller ones
(P = .07), and in periurban or rural sites than in urban
ones, although not signiﬁcantly (55.6% versus 32.4%, re-
spectively, P = .2).
TB Screening Practices
Screening practices to rule out active TB before starting
ART are shown in Table 3. They included contact history
(41 sites, 95.4%), weight loss (41 sites, 95.4%), fever
screening (38, 88.4%), cough screening (36, 83.7%),
chest radiograph (34, 79.1%), sputum microscopy (25,
58.1%), gastric aspiration (15, 34.9%), TST (15,
34.9%), mycobacterial culture (12, 27.9%), and induced
sputum microscopy (6, 14.0%). Some screening practices
varied across regions (Table 3). Gastric aspiration micros-
copy as part of screening practices was the least common
in Southern Africa (7.7% of sites included it in their screen-
ing practices) and most common in the Caribbean,
and Central and South America (100% of sites).
Mycobacterial culture as part of screening practices was
the least common in West Africa (0% of sites included it
in their screening practices) and most common in the
Caribbean, Central and South America (100% of sites).
The use of Xpert MTB/RIF for the screening of childhood
TB varied between 0% of sites in Asia-Paciﬁc, Central and
West Africa, and 33.3% of sites in the Caribbean, Central,
and South America.
TB Treatment Practices
The pediatric treatment regimens for both drug susceptible
andmultidrug resistant (MDR) TB are presented in Table 3
and Supplementary Table 1 (see online supplementary ma-
terial for Supplementary Table 1), respectively. The most
common ﬁrst-line regimen was composed of 2 months on
isoniazid, rifampicin, and pyrazinamide, followed by
4 months on isoniazid and rifampicin (14 sites, 32.6%).
MDR-TB regimens varied across sites (Supplementary
Table 1); 18 sites (41.9%) reported not to have a speciﬁc
MDR-TB regimen. IPT for children was given for 6 months
by 17 (39.5%) sites, for 9 months by 3 (7.0%) sites, and
lifelong by 1 (2.3%) site (Table 3). Thirteen (30.2%)
sites reported never providing IPT to HIV-infected children
after ruling out active TB.
Use of TB Diagnostics
The use of TB diagnostics was examined in 146 childrenwith
active TB seen and treated during the study period in 25 of
the participating ART programs from 16 countries.
Forty-nine (33.6%) children were seen in Asia-Paciﬁc, 43
(29.4%) in Southern Africa, 19 (13.0%) in West Africa, 15
(10.3%) in Central Africa, 15 (10.3%) in East Africa, and 5
(3.4%) in the Caribbean, and Central and South America.
Eighteen sites out of 43 did not contribute individual-level
patient data (3 in Asia-Paciﬁc, 2 in the Caribbean, Central
and South America, 3 in Central Africa, 4 in Southern
Africa, and 6 in West Africa) because the data collection
was not covered by the local IRB approval, or because of lo-
gistical reasons (eg, lack of staff resources).
Median age was 4.7 years (interquartile range [IQR] 1.6–
8.3), 78 (53.4%) were female, 113 (77.4%) had pulmonary
TB, and the median CD4 cell count was 280 cells/µL (inter-
quartile range: 53–773, Table 4). Overall, chest radiography
was performed in 125 (85.6%) children, sputum microsco-
py in 76 (52.0%), induced sputum microscopy in 38
(26.0%), gastric aspiration in 35 (24.0%), culture in 25
(17.1%), and Xpert MTB/RIF in 11 (7.5%).
DISCUSSION
We surveyed 43 pediatric sites participating in a network of
ART programs in low- and middle-income countries to as-
sess the availability and the use of diagnostic tools and
treatment for childhood TB, as well as screening practices.
We found that sputum microscopy and chest radiography
were the most commonly available TB diagnostic tools in
pediatric ART programs, followed by mycobacterial
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Table 1. Program Characteristics and Availability of Tuberculosis Diagnostic Tools in 43 ART Programs Treating Children in Low- andMiddle-Income Countries Within the
IeDEA Collaboration, Overall and by IeDEA Regions in 2012
Characteristic n (%) All Asia-Pacific
Caribbean, Central
and South America Central Africa East Africa Southern Africa West Africa
(n = 43) (n = 6) (n = 3) (n = 5) (n = 6) (n = 13) (n = 10)
Number of countries, n 23 4 3 4 3 5 4
Setting
Urban 34 (79.1) 6 (100) 3 (100) 5 (100) 2 (33.3) 9 (69.2) 9 (90)
Periurban 7 (16.3) 0 0 0 2 (33.3) 4 (30.8) 1 (10)
Rural 2 (4.6) 0 0 0 2 (33.3) 0 0
Level of care
Primary 13 (30.2) 0 0 0 2 (33.3) 9 (69.2) 2 (20)
Secondary 6 (14.0) 0 1 (33.3) 2 (40.0) 1 (16.7) 1 (7.7) 1 (10)
Tertiary 24 (55.8) 6 (100) 2 (66.7) 3 (60.0) 3 (50.0) 3 (23.1) 7 (70)
Patients treated at ART program
Children only 11 (25.6) 5 (83.3) 0 0 0 1 (7.7) 5 (50)
Adults and children 32 (74.4) 1 (16.7) 3 (100) 5 (100) 6 (100) 12 (92.3) 5 (50)
Number of children followed in HIV
care at time of surveya
33,432 2,066 (6.2) 422 (1.3) 1358 (4.1) 17,788 (53.2) 6861 (20.5) 4937 (14.7)
New pediatric TB cases per year,b n 1,606 79 42 78 247 879 83
Sputum smear microscopy available 43 (100) 6 (100) 3 (100) 5 (100) 6 (100) 13 (100) 10 (100)
Induced sputum microscopy availablec 23 (53.5) 5 (83.3) 1 (33.3) 3 (60.0) 2 (33.3) 7 (53.9) 5 (50.0)
Gastric aspirate microscopy availablec 27 (62.8) 6 (100) 3 (100) 4 (80) 1 (16.7) 4 (30.8) 9 (90)
Mycobacterial culture available 40 (93.0) 6 (100) 3 (100) 4 (80.0) 5 (83.3) 12 (92.3) 10 (100)
Xpert MTB/RIF available 16 (37.2) 1 (16.7) 1 (33.3) 1 (20.0) 3 (50.0) 7 (53.9) 3 (30.0)
Chest radiograph available 43 (100) 6 (100) 3 (100) 5 (100) 6 (100) 13 (100) 10 (100)
Tuberculin skin test available 26 (60.5) 5 (83.3) 2 (66.7) 5 (100) 1 (16.7) 4 (30.8) 9 (90.0)
Abbreviations: ART, antiretroviral treatment; HIV, human immunodeficiency virus; IeDEA, International Epidemiologic Databases to Evaluate AIDS; TB, tuberculosis.
aActively followed up at the time of the survey.
bMost recent year.
cInduced sputum and gastric aspiration microscopy were defined as available when these tools were reported as part of the TB screening recommendations in place at a given ART program.
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culture. Screening practices mainly relied on TB symptoms
and less frequently on the use of tools such as induced spu-
tum microscopy, gastric aspiration, or Xpert MTB/RIF.
Nearly a third of the participating ART programs reported
never providing IPT to HIV-infected children even after ac-
tive TB was ruled out. At the patient-level, Xpert MTB/RIF
and pediatric-speciﬁc sputum collection tools such as
induced sputum or gastric aspirate were used in only a
few children.
One quarter of the sites did not have access to either gas-
tric aspiration or induced sputum microscopy, and almost
two thirds did not have access to Xpert MTB/RIF, even
though these techniques have been shown to be safe and
useful for the diagnosis of childhood TB [15,19,20].A pre-
vious study surveyed pediatric ART programs of the IeDEA
collaboration in Asia-Paciﬁc and Africa and reported a
lower availability of TB diagnostic tools in 2010 compared
to our observations [21]. This may be partly explained by
the fact that the latter study restricted its analyses to the
availability of TB diagnostics on site directly, whereas
our study considered availability on or off site. When
restricting the deﬁnition to diagnostic tools for pediatric
TB accessible directly on site, the availability was indeed
drastically reduced. For instance, the availability of myco-
bacterial culture dropped from 93% to 21% when
restricting to sites with direct access only. A recent survey
by the International Center for AIDS Care and Treatment
Programs (ICAP) program showed a lower availability of
pediatric-speciﬁc TB diagnostic tools in HIV care centers
from sub-Saharan Africa than in the current study [22].
However, the ICAP program includes a larger proportion
of smaller sites in remote areas, and also fewer tertiary
care sites; hence, sophisticated diagnostic tools may be
scarcer in these settings.
Our study has several limitations. The description of
program characteristics reﬂects the situation observed at
the time of the survey. Therefore, we cannot exclude excep-
tional irregularities in the availability and use of TB diag-
nostic tools or treatments. Furthermore, the ART programs
participating in the IeDEA collaboration may not necessar-
ily represent all ART programs in a country or region.
Indeed, heterogeneity in TB diagnostic practices has been
shown within and between countries [23]. This survey cov-
ered a majority of urban sites and tertiary care sites, where
access to pediatric-speciﬁc TB diagnostic tools was likely to
be better than rural and lower level of care sites. Although
pediatric HIV/TB co-infected cases are rarer than adult
cases, we cannot exclude the possibility that some children
seen during the study period did not participate in the sur-
vey or were not screened for TB, which could explain the
Figure 1. Geographical distribution of the 43 pediatric human immunodeﬁciency virus treatment programs from the International Epidemiologic Databases to Evaluate
AIDS (IeDEA) network participating in the project. Numbers in parentheses indicate the number of participating sites in each country. Asterisk indicates a country with
at least one site treating pediatric patients only.
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Table 2. Program-Level Characteristics and Availability of Induced Sputum Microscopy, Gastric Aspirate Microscopy, Xpert MTB/RIF, Mycobacterial Culture, and
Tuberculin Skin Testing (TST) in 43 ART Programs Treating Children in Low- and Middle-Income Countries
Program Characteristic Total Induced Sputum
a Gastric Aspirationa Xpert MTB/RIF Mycobacterial Culture TST
n (%) P-value n (%) P-value n (%) P-value n (%) P-value n (%) P-value
Total 23 (53.5) 27 (62.8) 16 (37.2) 40 (93.0) 26 (60.5)
IeDEA region 0.59 0.001 0.561 0.607 0.003
Asia-Pacific 6 5 (83.3) 6 (100) 1 (16.7) 6 (100) 5 (83.3)
Caribbean, Central and South America 3 1 (33.3) 3 (100) 1 (33.3) 3 (100) 2 (66.7)
Central Africa 5 3 (60.0) 4 (80.0) 1 (20.0) 4 (80.0) 5 (100)
East Africa 6 2 (33.3) 1 (16.7) 3 (50.0) 5 (83.3) 1 (16.7)
Southern Africa 13 7 (53.9) 4 (30.8) 7 (53.9) 12 (92.3) 4 (30.8)
West Africa 10 5 (50.0) 9 (90.0) 3 (30.0) 10 (100) 9 (90.0)
Setting 0.17 0.040 0.200 0.584 0.008
Urban 34 20 (58.8) 24 (70.6) 11 (32.4) 32 (94.1) 24 (70.6)
Periurban and rural 9 3 (33.3) 3 (33.3) 5 (55.6) 6 (85.7) 1 (14.3)
Level of care 0.36 0.005 0.727 0.557 0.149
Primary 13 6 (46.2) 4 (30.8) 6 (46.2) 12 (92.3) 5 (38.5)
Secondary 6 2 (33.3) 3 (50.0) 2 (33.3) 5 (83.8) 4 (66.7)
Tertiary 23 15 (62.5) 20 (83.3) 8 (33.3) 23 (95.8) 17 (70.8)
Patients treated at ART program 0.14 0.003 0.025 0.292 0.093
Children only 11 8 (72.7) 11 (100) 1 (9.1) 11 (100) 9 (81.8)
Children and adults 32 15 (46.9) 16 (50.0) 15 (46.9) 29 (90.6) 17 (53.1)
Number of children followed in HIV
care at time of surveyb
0.33 0.228 0.011 0.976 0.329
<500 29 17 (58.6) 20 (69.0) 7 (24.1) 27 (93.1) 19 (65.5)
500 and above 14 6 (42.8) 7 (50.0) 9 (64.3) 13 (92.9) 7 (50.0)
New TB cases per yearc 0.054d 0.086d 0.071d 0.949d 0.339d
<10 18 13 (72.2) 14 (77.8) 4 (22.2) 17 (94.4) 13 (72.2)
10–29 10 3 (30.0) 6 (60.0) 3 (30.0) 9 (90.0) 6 (60.0)
30 13 5 (38.5) 5 (38.5) 8 (61.5) 12 (92.3) 6 (46.1)
Missing information 2 2 (100) 2 (100) 1 (50.0) 2 (100) 1 (50.0)
Results for sputum microscopy and chest X-ray are not shown because these diagnostic tools were available at all sites.
P values from χ2 tests.
Abbreviations: ART, antiretroviral treatment; TB, tuberculosis; TST, tuberculin skin testing.
aInduced sputum and gastric aspiration microscopy were defined as available when these tools were reported as part of the TB screening recommendations in place at a given ART program.
bActively followed up at the time of the survey.
cMost recent year.
dP values calculated excluding sites with missing information.
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Table 3. Practices Related to Tuberculosis Screening, Isoniazid Preventive Therapy, and Tuberculosis Treatment at 43 ART Programs Treating Children in Low- and
Middle-Income Countries Within the IeDEA Collaboration, Overall and by IeDEA Regions in 2012
ART Program Data n (%) All Asia- Pacific
Caribbean, Central and
South America Central Africa East Africa Southern Africa West Africa
Total number of ART programs 43 6 3 5 6 13 10
TB screening practices before starting ARTa
Cough 36 (83.7) 5 (83.3) 3 (100) 5 (100) 5 (83.3) 12 (92.3) 6 (60.0)
Fever 38 (88.4) 5 (83.3) 3 (100) 5 (100) 6 (100) 11 (84.6) 8 (80.0)
Night sweats 38 (88.4) 5 (83.3) 3 (100) 5 (100) 5 (83.3) 12 (92.3) 8 (80.0)
Weight loss 41 (95.4) 6 (100) 3 (100) 4 (80.0) 6 (100) 12 (92.3) 10 (100)
Contact history 41 (95.4) 6 (100) 3 (100) 5 (100) 5 (83.3) 12 (92.3) 10 (100)
Sputum smear microscopy 25 (58.1) 4 (66.7) 2 (66.7) 3 (60.0) 3 (50.0) 6 (46.2) 7 (70.0)
Induced sputum microscopy 6 (14.0) 0 1 (33.3) 0 1 (16.7) 3 (23.1) 1 (10.0)
Gastric aspirate microscopy 15 (34.9) 5 (83.3) 3 (100) 3 (60.0) 0 1 (7.7) 3 (30.0)
Chest radiograph 34 (79.1) 6 (100) 3 (100) 4 (80.0) 4 (66.7) 9 (69.2) 8 (80.0)
Culture 12 (27.9) 3 (50.0) 3 (100) 1 (20.0) 1 (16.7) 4 (30.8) 0
Xpert MTB/RIF 3 (7.0) 0 1 (33.3) 0 1 (16.7) 1 (7.7) 0
TST 15 (34.9) 3 (50.0) 2 (66.7) 1 (20.0) 0 3 (23.1) 6 (60.0)
Administration of IPT
Never 13 (30.2) 1 (16.7) 0 1 (20.0) 4 (66.6) 3 (23.1) 4 (40.0)
Not applicable 6 (14.0) 0 0 1 (20.0) 0 2 (15.4) 3 (30.0)
Always (any age) 4 (9.3) 1 (16.7) 1 (33.3) 0 1 (16.7) 1 (7.7) 0
Only children >12 months 3 (7.0) 1 (16.7) 0 1 (20.0) 1 (16.7) 0 0
Only if TST-positive 2 (4.6) 0 2 (66.7) 0 0 0 0
Other 15 (34.9) 3 (49.9) 0 2 (40.0) 0 7 (53.8) 3 (30.0)
Duration of IPT
6 months 17 (39.5) 4 (66.7) 0 3 (60.0) 1 (16.7) 7 (53.9) 2 (20.0)
9 months 3 (7.0) 1 (16.7) 1 (33.3) 0 1 (16.7) 0 0
Lifetime 1 (2.3) 0 1 (33.3) 0 0 0 0
Others 22 (51.2) 1 (16.7) 1 (33.3) 2 (40.0) 4 (66.7) 6 (46.1) 8 (80.0)
TB treatment regimen (first-line)
2HRZ, 4HR 14 (32.6) 1 (16.7) 0 3 (60.0) 3 (50.0) 3 (23.1) 4 (40.0)
2HRZE, 4HR 10 (23.7) 2 (33.3) 1 (33.3) 1 (20.0) 1 (16.7) 4 (30.7) 1 (10.0)
Other 13 (30.2) 3 (50.0) 0 1 (20.0) 1 (16.7) 3 (23.1) 5 (50.0)
None 6 (13.9) 0 2 (66.6) 0 1 (16.7) 3 (23.1) 0
MDR-TB treatment regimen
Specific regimen reportedb 8 (18.6) 1 (16.7) 0 2 (40.0) 0 1 (7.7) 5 (50.0)
No specific regimen reported 18 (41.9) 0 2 (66.7) 2 (40.0) 3 (50.0) 9 (69.2) 2 (20.0)
Individualizedc 9 (20.9) 5 (83.3) 0 0 2 (33.3) 2 (15.4) 0
Referral 8 (18.6) 0 1 (33.3) 1 (20.0) 0 1 (7.7) 5 (50.0)
Abbreviations: ART, antiretroviral treatment; IPT, isoniazid preventive therapy; leDEA, International Epidemiologic Databases to Evaluate AIDS; MDR, multidrug-resistant; TB, tuberculosis; TB treatment regimens:
E, ethambutol; H, isoniazid; R, rifampicin; Z, pyrazinamide; TST, tuberculin skin testing.
aMultiple answers were possible.
bSee Supplementary Table 1.
cIndividualized MDR-TB treatment regimens based on drug susceptibility testing and/or availability of drugs.
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low number of patients included in the patient data collec-
tion. This might potentially reduce the generalizability of
the results from the individual-level patient data analyses.
The strength of our study was the inclusion of sites in var-
ious regions, which is likely to provide a global representa-
tion of TB care practices in ART programs. In addition, the
structure of the survey allowed comparing the availability
of pediatric TB diagnostic tools with their use at the patient
level. This provides information on the important gap be-
tween access to tools and their actual use for diagnosis.
In conclusion, we found that childhood TB diagnostic
tools are still infrequently available and used in pediatric
ART programs of low- and middle-income countries. The
use of TB diagnostic tools, particularly rapid molecular di-
agnostics such as Xpert MTB/RIF, remain a challenge in
pediatric ART programs worldwide, despite an increasing
number of studies demonstrating that these tests are valid
and useful in children and in adults [15,24,25]. The success-
ful rollout of XpertMTB/RIF certainly requires that the ma-
chines be made available close to points of care and used
within an algorithm process to increase the TB diagnosis ac-
curacy according to the prevalence context. Beyond the ma-
chine provision, the success of Xpert MTB/RIF will need to
be accompanied by adequate training and equipment main-
tenance, regular reagent supply, and affordable cost to the
patient in order to increase use. The paucibacillary nature
of TB in children is associated with low yield of microscopy
and cultures. Therefore, the scale-up of highly sensitive mo-
lecular diagnostics such asXpertMTB/RIF, alone or in com-
bination with additional diagnostics, may become a key
element in ART programs caring for HIV-infected children
in high TB prevalence settings.
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New case 132 (90.4)
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Night sweats, n (%) 60 (41.1)
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency
virus; IQR, interquartile range; leDEA, International Epidemiologic Databases
to Evaluate AIDS; TB, tuberculosis; WHO, World Health Organization.
aAt the start of ART.
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